No Data
Tencent Invests in Canadian Challenger Bank Neo Financial
Selected announcements from Gelonghui (Hong Kong stocks) | bosideng (03998.HK) mid-term net profit increased by 23.0% to 1.13 billion yuan, proposing an interim dividend of 6.0 Hong Kong cents per share.
【Today's Focus】 Bosideng (03998.HK) reports a 23.0% increase in mid-term net profit to 1.13 billion yuan and plans to pay a mid-term dividend of 6.0 Hong Kong cents per share. Bosideng (03998.HK) announced the mid-term results for the six months ending September 30, 2024, with revenue increasing by 17.8% to approximately 8.804 billion yuan. The profit attributable to the company's equity shareholders rose by 23.0% to approximately 1.13 billion yuan. The earnings per share are 10.35 yuan. The board of directors declared a mid-term dividend of 6.0 Hong Kong cents per share for ordinary shares. The group will adhere to the mission of "China Bosideng, warming the world" as it aims to be a global leader.
AI guru started to shuffle madly.
Integration is on the rise.
Tencent (00700.HK) spent 0.7 billion Hong Kong dollars on repurchasing 1.75 million shares on November 28th.
Gelonghui, November 28 - tencent (00700.HK) announced that on November 28, 2024, it will spend 0.7 billion Hong Kong dollars to repurchase 1.75 million shares, with a repurchase price of 397.6-403.8 Hong Kong dollars per share.
gtja: Cloud applications and terminal asia vets drive industrial upgrades; AI track companies are welcoming significant development opportunities.
Tai Jun An released a research report stating that with the acceleration of AI application processes and the continuous emergence of scenario implementation cases, coupled with the dual drive of cloud applications and asia vets for industrial upgrades, companies in the AI track are ushering in important development opportunities.
Glory Announces (Hong Kong Stock) | cms (00867.HK): innovative drug GLP-1R/GCGR dual agonist CMS-D005 receives drug clinical trial approval notification.
Today's focus: cms (00867.HK): Innovative drug GLP-1R/GCGR dual agonist CMS-D005 receives drug clinical trial approval notification cms (00867.HK) announcement, the group's independently developed innovative drug CMS-D005 injection (CMS-D005) received the drug clinical trial approval notification issued by the China National Medical Products Administration on November 27, 2024. NMPA has approved the group to evaluate the safety, tolerability, and pharmacokinetics of CMS-D005 in Chinese healthy, overweight, and obese adult subjects.
No Data
No Data
No Data
This page we’re on is probably where you want to direct your message, much better insight on the Asian markets. Have a good day. 
